DelveInsight’s “Dengue Fever Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Dengue Fever, historical and forecasted epidemiology as well as the Dengue Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Dengue Fever market report provides current treatment practices, emerging drugs, Dengue Fever market share of the individual therapies, and current and forecasted Dengue Fever market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Dengue Fever treatment practices/algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Dengue Fever Overview
Dengue fever is a disease caused by four dengue viruses spread by the Aedes aegypti mosquito. The Centers for Disease Control and Prevention (CDC) estimates that at least 400 million cases of Dengue fever occur across the globe every year. It is also known as breakdown fever due to the severity of muscle spasms and joint pain, and fever, or seven-day fever because of the usual duration of symptoms. It has an incubation period of 5 to 7 days and it follows 3 phases febrile, critical and convulsant.
Dengue Fever Epidemiology Insights:
-
Based on 48 hospitalized patients in whom Dengue Fever was diagnosed, a prevalence of 3.6 per 1,000 hospitalized patients was calculated. The second study was a prospective cohort study carried out in Mexico over a period of 10 months. This study demonstrated a prevalence of 7 per 1,000 hospitalized patients. In South Korea, a mandatory electronic reporting system for immunologically mediated Dengue Fever could identify 2,652 cases of ADR in a total of 55,432 hospitalizations over a period of 7 months. The study included cutaneous as well as non-cutaneous reactions. An allergist classified 532 reactions to be “significant drug hypersensitivity reactions”. 100 of these were new events, and 70% of them had a cutaneous manifestation. The overall incidence of ADRs was estimated to be 1.8 per 1,000 hospitalizations.
Dengue Fever Epidemiology Segmentation
-
Dengue Fever prevalent cases
-
Dengue Fever diagnostic cases
-
Dengue Fever treated cases
Dengue Fever Market Outlook
The Dengue Fever market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Dengue Fever market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of the Dengue Fever market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Learn more by requesting for sample @ Dengue Fever Market Trends
Dengue Fever Key Companies
-
Takeda
-
Sanofi
-
And many others
Table of Contents
-
Key Insights
-
Report Introduction
-
Executive Summary of Dengue Fever
-
Disease Background and Overview
-
Epidemiology and patient population
-
The United States
-
EU 5
-
Dengue Fever Emerging Therapies
-
Dengue Fever Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Dengue Fever Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Click here to read more about Dengue Fever Market Trends
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/